Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal mode of action of semaglutide in type 2 diabetes with chronic kidney disease
2020-000828-19Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Semaglutide once weekly with Placebo once weekly (2 arms). Primary endpoint: Change in kidney oxygenation (cortex). Started Dec 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2020-000828-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000828-19.